Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie-Reference-Cited by-同舟云学术

Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie

Published:2009-10 Issue:10 Volume:20 Page:1667-1673
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Lorenzen S.,Schuster T.,Porschen R.,Al-Batran S.-E.,Hofheinz R.,Thuss-Patience P.,Moehler M.,Grabowski P.,Arnold D.,Greten T.,Müller L.,Röthling N.,Peschel C.,Langer R.,Lordick F.

Funder

Klinikum rechts der Isar, Technische Universität München; Merck-Serono KGaA; Merck-Serono to FL.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/20/10/1667/613344/mdp069.pdf

Reference28 articles.

1. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer;Bleiberg;Eur J Cancer,1997

2. Management of esophageal cancer;Ilson;Oncology (Williston Park),1996

3. Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus;Polee;Anticancer Drugs,2001